Abstract：
UNASSIGNED: There is a need for new therapies that can enhance response rates and broaden the number of cancer indications where immunotherapies provide clinical benefit. CD40 targeting therapies provide an opportunity to meet this need by promoting priming of tumor-specific T cells and reverting the suppressive tumor microenvironment. This is supported by emerging clinical evidence demonstrating the benefits of immunotherapy with CD40 antibodies in combination with standard of care chemotherapy.
UNASSIGNED: This review is focused on the coming wave of next-generation CD40 agonists aiming to improve efficacy and safety, using new approaches and formats beyond monospecific antibodies. Further, the current understanding of the role of different CD40 expressing immune cell populations in the tumor microenvironment is reviewed.
UNASSIGNED: There are multiple promising next-generation approaches beyond monospecific antibodies targeting CD40 in immuno-oncology. Enhancing efficacy is the most important driver for this development, and approaches that maximize the ability of CD40 to both remodel the tumor microenvironment and boost the anti-tumor T cell response provide great opportunities to benefit cancer patients. Enhanced understanding of the role of different CD40 expressing immune cells in the tumor microenvironment may facilitate more efficient clinical development of these compounds.
UNASSIGNED: This review is focused on the coming wave of next-generation CD40 agonists aiming to improve efficacy and safety, using new approaches and formats beyond monospecific antibodies. Further, the current understanding of the role of different CD40 expressing immune cell populations in the tumor microenvironment is reviewed.
UNASSIGNED: There are multiple promising next-generation approaches beyond monospecific antibodies targeting CD40 in immuno-oncology. Enhancing efficacy is the most important driver for this development, and approaches that maximize the ability of CD40 to both remodel the tumor microenvironment and boost the anti-tumor T cell response provide great opportunities to benefit cancer patients. Enhanced understanding of the role of different CD40 expressing immune cells in the tumor microenvironment may facilitate more efficient clinical development of these compounds.
摘要：
■在免疫疗法提供临床益处的情况下，需要能够提高反应率并扩大癌症适应症数量的新疗法。CD40靶向疗法通过促进肿瘤特异性T细胞的引发和恢复抑制性肿瘤微环境来提供满足这种需求的机会。这得到了新出现的临床证据的支持，这些证据证明了CD40抗体与标准护理化学疗法组合的免疫疗法的益处。
■这篇综述的重点是即将到来的新一代CD40激动剂，旨在提高疗效和安全性，使用单特异性抗体以外的新方法和形式。Further,综述了目前对不同表达CD40的免疫细胞群体在肿瘤微环境中的作用的理解.
■在免疫肿瘤学中，除了靶向CD40的单特异性抗体外，还有多种有前途的下一代方法。增强功效是这一发展的最重要驱动力，以及最大化CD40重塑肿瘤微环境和增强抗肿瘤T细胞反应的能力的方法提供了使癌症患者受益的巨大机会。增强对不同CD40表达免疫细胞在肿瘤微环境中的作用的理解可以促进这些化合物的更有效的临床开发。
■这篇综述的重点是即将到来的新一代CD40激动剂，旨在提高疗效和安全性，使用单特异性抗体以外的新方法和形式。Further,综述了目前对不同表达CD40的免疫细胞群体在肿瘤微环境中的作用的理解.
■在免疫肿瘤学中，除了靶向CD40的单特异性抗体外，还有多种有前途的下一代方法。增强功效是这一发展的最重要驱动力，以及最大化CD40重塑肿瘤微环境和增强抗肿瘤T细胞反应的能力的方法提供了使癌症患者受益的巨大机会。增强对不同CD40表达免疫细胞在肿瘤微环境中的作用的理解可以促进这些化合物的更有效的临床开发。
